Thomas Yau, MBBS, of the University of Hong Kong, discusses this triplet combination, which yielded better responses than doublet combination therapy in patients with advanced liver cancer, but with m...
Brian M. Wolpin, MD, of Dana-Farber Cancer Institute, discusses a noninvasive blood test evaluating methylation of circulating free DNA. In his study, the blood test detected multiple gastrointestinal...
Danielle S. Bitterman, MD, of the Harvard University Radiation Oncology Program and Massachusetts General Hospital, discusses an analysis of genomic and clinical data from 97 patients with pancreatic ...
Thibaud Kössler, MD, PhD, of Geneva University Hospital, discusses the first trial to study the efficacy and safety of anti–PD-1 immunotherapy plus short-course radiotherapy in localized microsatellit...
Eyal Meiri, MD, of the Cancer Treatment Centers of America at Southeastern Regional Medical Center, discusses his findings on heavily pretreated patients with colorectal cancer with high tumor mutatio...
Franck Pagès, MD, PhD, of the Hôpital Européen Georges Pompidou, discusses study findings from the prospective IDEA France cohort study of patients with stage III colon cancer treated with mFOLFOX6. T...
Van K. Morris, MD, of The University of Texas MD Anderson Cancer Center, discusses the COBRA study, which is examining circulating tumor DNA and its ability to predict whether patients with resected s...
Peter R. Galle, MD, of the University Medical Center, Mainz, discusses patient-reported outcomes from this phase III study, which showed the combination of atezolizumab plus bevacizumab vs sorafenib i...
Zev A. Wainberg, MD, of the UCLA Medical Center, discusses the first subset analysis of how a combined positive score in gastric and gastroesophageal junction cancers related to the efficacy of pembro...
Heinz-Josef Lenz, MD, of USC Norris Comprehensive Cancer Center, discusses how treating microsatellite instability–high/DNA mismatch repair–deficient metastatic colorectal cancer with nivolumab once e...
Scott Kopetz, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings from the BEACON CRC trial, which had demonstrated that the triplet regimen of encorafenib, cet...
Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II trial findings showing that cisplatin and gemcitabine, with or without veliparib, exceeded a prespecified response...